SCHEMBL5464906

SCHEMBL5464906

COc1ccc2c(c1)c(C=C1C(=O)Nc3ccccc31)cn2C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 11/20 0.72
FCER2 P06734 5/20 0.72
NTRK1 P04629 6/20 0.71
MAP3K5 Q99683 1/20 0.71
NTRK3 Q16288 4/20 0.71
NTRK2 Q16620 4/20 0.71
PRKD3 O94806 1/20 0.64
ABL1 P00519 1/20 0.64
RET P07949 1/20 0.64
PDGFRB P09619 1/20 0.64
LTK P29376 1/20 0.64
KDR P35968 1/20 0.64
MAP2K2 P36507 1/20 0.64
FLT3 P36888 1/20 0.64
CSNK1A1 P48729 1/20 0.64
CDK8 P49336 1/20 0.64
CDK7 P50613 1/20 0.64
MAP2K1 Q02750 1/20 0.64
MST1R Q04912 1/20 0.64
AURKB Q96GD4 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464897 1.00 SYK (0.72) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL14448940 0.91 NTRK1 (0.71) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5481903 0.91 NTRK1 (0.71) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5481884 0.91 NTRK1 (0.71) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5477303 0.84 NTRK1 (0.74) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5477310 0.84 NTRK1 (0.74) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL14448833 0.84 NTRK1 (1.00) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5469776 0.84 NTRK1 (1.00) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL5469785 0.84 NTRK1 (1.00) SYKFCER2NTRK1MAP3K5NTRK3
SCHEMBL19980738 0.83 SYK (1.00) SYKFCER2NTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 SYK 3234/4885FCER2 208/4885NTRK1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.